Accueil>>Lipids>> Glycerophospholipids>>2-O-methyl PAF C-18 (hydrate)

2-O-methyl PAF C-18 (hydrate) (Synonyms: Edelfosine, ET-18-OCH3, 1Ooctadecyl2Omethylsnglyceryl3phosphorylcholine)

Catalog No.GC48450

A synthetic PAF analog

Products are for research use only. Not for human use. We do not sell to patients.

2-O-methyl PAF C-18 (hydrate) Chemical Structure

Taille Prix Stock Qté
5mg
72,00 $US
En stock
10mg
137,00 $US
En stock
50mg
576,00 $US
En stock
100mg
977,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

2-O-methyl-PAF C-18 is a synthetic PAF analog which contains a methyl group, attached by an ether linkage, at the sn-2 position. It has been shown to mediate a number of biological responses including decreasing plasma membrane fluidity and inhibiting tumor cell invasiveness in embryonic chick heart.1 In rat astrocytes, 2-O-methyl PAF C-18 causes the release of large quantities of nitric oxide by a pathway involving activation of nitric oxide synthase.2

1.van Blitterswijk, W.J., Hilkmann, H., and Storme, G.A.Accumulation of an alkyl lysophospholipid in tumor cell membranes affects membrane fluidity and tumor cell invasionLipids22(11)820-823(1987) 2.Cardile, V., Jiang, X., Renis, M., et al.Effects of ether lipid 1-O-octadecyl-2-methoxy-rac-glycero-3-phosphocholine and its analogs PAF and CPAF on the release of nitric oxide in primary cultures of rat astrocytesBrain Research715(1-2)98-103(1996)

Avis

Review for 2-O-methyl PAF C-18 (hydrate)

Average Rating: 5 ★★★★★ (Based on Reviews and 18 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 2-O-methyl PAF C-18 (hydrate)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.